Last reviewed · How we verify
Corn starch
Corn starch, marketed by Peking University People's Hospital, is a product primarily indicated for absorbing excess moisture. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the lack of revenue data and key trial results, which may limit the drug's market visibility and competitive positioning.
At a glance
| Generic name | Corn starch |
|---|---|
| Sponsor | Peking University People's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Absorbing Excess Moisture
- Protecting Against Irritating Friction
Common side effects
Key clinical trials
- Effects of Probiotics on Respiratory Tract Infections in Children: A Randomized, Placebo-Controlled Interventional Study (PHASE2)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease (PHASE2)
- Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients (PHASE2)
- Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis (PHASE2)
- Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome (PHASE2)
- Caffeine Supplementation and Strength Endurance in Brazilian Jiu-jitsu Athletes (NA)
- L-serine and Strength Training in the Elderly (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |